根据名称进行药物检索

Digoxin Tablets 与 Zithromax Tri-Pak

Digoxin Tablets 与 Zithromax Tri-Pak互相作用以及同时服用的可能性。

检测结果:

Digoxin Tablets <> Zithromax Tri-Pak

现实性: 11.06.2023 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

谈谈你的医生之前采用这种药物在一起，与阿齐霉素。结合这些药物可能增加的血液水平和影响的地高辛。你的医生可以规定替代品，不进行互动，或者可能需要一剂量的调整或更频繁的监测通过你的医生到安全地使用这两种药物。联系您的医生，如果你遇到恶心、呕吐、腹泻、食欲丧失、视觉障碍(视力模糊；光晕约的对象；绿色或黄色视)，或异常快速或慢或不均衡的心跳，因为这些可能的迹象和症状的过度地高辛的水平。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

监测：大环内酯类抗生素，抑制的P-糖蛋白质可能增加等离子浓度的地高辛。拟议的机制是抑制的P-糖蛋白介肠流出和/或肾管分泌的地高辛。相互作用已经描述了在许多情况下报告在医学文献中，其中大多数涉及克拉，一个强有力的P-糖蛋白抑制剂。一些病人具有示临床体征符合地高辛的毒性，包括潜在的致命性心律失常。暴露于大环内酯，具体地说克拉、阿奇霉素和红霉素已被确定为风险因素这种药物的毒性。基于人口的、案例控制研究中使用的记录，加拿大安大略省的行政管理的健康数据库，从1994年至2000年确定的1051情况下，患者曾住院的地高辛的毒性。这些患者中约12倍，可能已经收到一方为克拉，在前一周相比，控制没有地高辛的毒性(n=51,896). 总体而言，27的情况下病人(2.6%)已经暴露拉霉素在前一周，相比101控制(0.2%)，其中表示的经调整的赔率比例为11.7. 大会第五十五患者(5.2%)已经暴露于克拉内所述的3个星期，相比274控制(0.5%)，表示调整或8.5. 随后的研究中使用数据从1993年到2008年相同的数据库，并特别注重大环内酯类诱发的地高辛的毒性发现风险明显高的病人收到了克拉内先前的2个星期比以控制没有得到抗生素(调整或=14.8). 危险的地高辛的毒性高4倍以下的治疗与克拉比与阿齐或红霉素(调整或=3.71和3.69，分别)。虽然小数据存在的相互作用也可能会发生洋地黄毒苷. 两起案件的怀疑阿齐诱导洋地黄毒苷毒性已有文献报道。

管理：谨慎建议时地高辛洋地黄毒苷或结合使用大环内酯类抗生素抑制剂的P-糖蛋白。血清水平洋地黄和药理效果，应密切监测和剂量进行相应的调整，特别是以下启动或中止的大环内酯的患者中稳定在他们的毛地黄方案。患者应建议通知他们的医生如果他们的经验的迹象毛地黄毒性，如恶心、厌食症、视觉障碍，脉搏缓慢，或者不规则心跳。

来源

Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR "Inactivation of digoxin by the gut flora: reversal by antibiotic therapy." N Engl J Med 305 (1981): 789-94
Nawarskas JJ, McCarthy DM, Spinler SA "Digoxin toxicity secondary to clarithromycin therapy." Ann Pharmacother 31 (1997): 864-6
Ten Eick AP, Sallee D, Preminger T, Weiss A, Reed MD "Possible drug interaction between digoxin and azithromycin in a young child." Clin Drug Investig 20 (2000): 61-4
Hughes J, Crowe A "Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics." J Pharmacol Sci 113 (2010): 315-24
Ford A, Smith LC, Baltch AL, Smith RP "Clarithromycin-induced digoxin toxicity in a patient with AIDS." Clin Infect Dis 21 (1995): 1051-2
Rodin SM, Johnson BF "Pharmacokinetic interactions with digoxin." Clin Pharmacokinet 15 (1988): 227-44
Balayssac D, Authier N, Cayre A, Coudore F "Does inhibition of P-glycoprotein lead to drug-drug interactions?" Toxicol Lett 156 (2005): 319-29
Rengelshausen J, Goggelmann C, Burhenne J, et al. "Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction." Br J Clin Pharmacol 56 (2003): 32-38
Lee CY, Marcotte F, Giraldeau G, Koren G, Juneau M, Tardif JC "Digoxin toxicity precipitated by clarithromycin use: case presentation and concise review of the literature." Can J Cardiol 27 (2011): 870 e15-6
Alkadi H, Mosfer M, Alkatheri M "Clarithromycin and azithromicin induced-digoxin toxicity in patients under digoxin therapy." Clin Res Cardiol 96 (2007): 424
Tanaka H, Matsumoto K, Ueno K, et al. "Effect of clarithromycin on steady-state digoxin concentrations." Ann Pharmacother 37 (2003): 178-81
Midoneck SR, Etingin O "Clarithromycin-related toxic effects of digoxin." N Engl J Med 333 (1995): 1505
Kiran N, Azam S, Dhakam S "Clarithromycin induced digoxin toxicity: case report and review." J Pak Med Assoc 54 (2004): 440-1
Kurata Y, Ieiri I, Kimura M, et al. "Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein." Clin Pharmacol Ther 72 (2002): 209-19
Lindenbaum J, Tse-Eng D, Butler VP, Rund DG "Urinary excretion of reduced metabolites of digoxin." Am J Med 71 (1981): 67-74
Chan AL, Wang MT, Su CY, Tsai FH "Risk of digoxin intoxication caused by clarithromycin-digoxin interactions in heart failure patients: a population-based study." Eur J Clin Pharmacol 65 (2009): 1237-43
Maxwell DL, Gilmour-White SK, Hall MR "Digoxin toxicity due to interaction of digoxin with erythromycin." BMJ 298 (1989): 572
Nordt SP, Williams SR, Manoguerra AS, Clark RF "Clarithromycin induced digoxin toxicity." J Accid Emerg Med 15 (1998): 194-5
Zapater P, Reus S, Tello A, Torrus D, Perez-Mateo M, Horga JF "A prospective study of the clarithromycin-digoxin interaction in elderly patients." J Antimicrob Chemother 50 (2002): 601-6
Ten Eick AP, Reed MD "Hidden dangers of coadministration of antibiotics and digoxin in children: focus on azithromycin." Curr Ther Res 61 (2000): 148-60
Gooderham MJ, Bolli P, Fernandez PG "Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin." Ann Pharmacother 33 (1999): 796-9
"Product Information. Lanoxicaps (digoxin)." Glaxo Wellcome, Research Triangle Park, NC.
Bizjak ED, Mauro VF "Digoxin-macrolide drug interaction." Ann Pharmacother 31 (1997): 1077-82
Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF "P-glycoprotein-mediated intestinal and biliary digoxin transport in humans." Clin Pharmacol Ther 73 (2003): 223-31
Gomes T, Mamdani MM, Juurlink DN "Macrolide-induced digoxin toxicity: a population-based study." Clin Pharmacol Ther 86 (2009): 383-6
Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17
Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, Sasayama S, Inui K "Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein." Clin Pharmacol Ther 64 (1998): 123-8
Guerriero SE, Ehrenpreis E, Gallagher KL "Two cases of clarithromycin-induced digoxin toxicity." Pharmacotherapy 17 (1997): 1035-7
Thalhammer F, Hollenstein UM, Locker GJ, et al "Azithromycin-related toxic effects of digitoxin." Br J Clin Pharmacol 45 (1998): 91-2
Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA "Drug-drug interactions among elderly patients hospitalized for drug toxicity." JAMA 289 (2003): 1652-8
Tsutsumi K, Kotegawa T, Kuranari M, et al. "The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers." J Clin Pharmacol 42 (2002): 1159-64
Corallo CE, Rogers IR "Roxithromycin-induced digoxin toxicity." Med J Aust 165 (1996): 433-4
Gurley BJ, Swain A, Williams DK, Barone G, Battu SK "Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics." Mol Nutr Food Res 52 (2008): 772-9
Friedman HS, Bonventre MV "Erythromycin-induced digoxin toxicity." Chest 82 (1982): 202
Brown BA, Wallace RJ, Griffith DE, Warden R "Clarithromycin-associated digoxin toxicity in the elderly." Clin Infect Dis 24 (1997): 92-3
Laberge P, Martineau P "Clarithromycin-induced digoxin intoxication." Ann Pharmacother 31 (1997): 999-1002
Trivedi S, Hyman J, Lichstein E "Clarithromycin and digoxin toxicity." Ann Intern Med 128 (1998): 604
Hui J, Wang YMC, Chandrasekaran A, Geraets DR, Caldwell JH, Robertson LW, Reuning RH "Disposition of tablet and capsule formulations of digoxin in the elderly." Pharmacotherapy 14 (1994): 607-12
Eberl S, Renner B, Neubert A, et al. "Role of p-glycoprotein inhibition for drug interactions : evidence from in vitro and pharmacoepidemiological studies." Clin Pharmacokinet 46 (2007): 1039-49
Hirata S, Izumi S, Furukubo T, et al. "Interactions between clarithromycin and digoxin in patients with end-stage renal disease." Int J Clin Pharmacol Ther 43 (2005): 30-6
Morton MR, Cooper JW "Erythromycin-induced digoxin toxicity." DICP 23 (1989): 668-70